DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)
Jupid | $840,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Creati AI | $20,000,000 | (May 1, 2026)
Manifest OS | $60,000,000 | (May 1, 2026)
Iterative Health | $77,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Illuminant Surgical | $8,400,000 | (May 1, 2026)
BioOrbit | $13,334,811 | (May 1, 2026)
Parallel Web Systems | $100,000,000 | (Apr 30, 2026)
Fence | $20,000,000 | (Apr 30, 2026)
Certifyde | $2,000,000 | (Apr 30, 2026)